<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180411039267N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-15</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of hemodynamic and respiratory changes in anesthesia and laparoscopic gynecological surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the changes in hemodynamic and respiratory parameters in two methods of spinal anesthesia versus general anesthesia in diagnostic gynecologic laparoscopy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>74</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54150</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Prevention, Randomization description: Using a table of random numbers that includes numbers from 1 to 74 and with each referral up to 74th patient,each time we randomly select a number from the number table(by calculators random numbers system and each number will have a chance to happen only once) and depending on what number comes up,each patient is placed in one of the two intervention groups (37 people) and the control group (37 people).Thus,if our random number was odd, the patient will be in the intervention group and will undergo spinal anesthesia and if our random number was even,the patient will undergo general anesthesia in the control group, Blinding description: In this study, the anesthesiologist is fully aware of the groupings because he has to induce general anesthesia and anesthesia on patients. The same anesthesiologist and nurse collected the data during the operation and recovery, and the patient are Conscious of anesthesia or numbness,
and only the data analyzer is blind to the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Comparison of hemodynamic and respiratory changes in spinal anesthesia and general anesthesia in diagnostic laparoscopy in women.</hc_freetext>
      <i_freetext>Intervention 1: Control group:37 patients will be placed under general anesthesia with induction and maintenance of anesthesia with 1% intravenous propofol drug of Dongkook pharmaco company made in Korea and endotracheal intubation will be performed for controlled breathing during surgery and hemodynamic and respiratory consequences (such as Systolic and diastolic blood pressure, mean arterial pressure, heart rate, saturation of peripheral oxygen, severity of nausea and vomiting, severity of pain )during and after surgery will be assessed. Intervention 2: Intervention group:37 patients undergoing spinal anesthesia with spinal injection of topical anesthetic bupivacaine 5% hyperbaric manufactured by aspen company and spontaneous respiration will be maintained and hemodynamic and respiratory consequences (such as systolic and diastolic blood pressure, mean arterial pressure, heart rate, saturation of peripheral oxygen, severity of nausea and vomiting, severity of pain)during and after surgery will be assessed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data can be shared after making peoples unrecognizable.

When:
Starting 6 months after publication

To whom:
Documents will be available for people working in academic institutions and also people working in businesses

Conditions:
There will be no specific limitations to the utilization of the data

Where to obtain:
Dr .Reyhaneh Abri, Department of Anesthesiology, Faculty of Medicine, Golgasht Street, Tabriz East Azarbaijan Islamic Republic of Iran ,Phone+98 413 3341994, Fax+98 41 33341994 , re.abri@tbzmed.ac.ir

How to obtain:
Applicants will access the data from the present study by sending an email to the responsible author for a maximum of one week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reyhaneh Abri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Operating room-alzahra hospital- south artesh st</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138663134</zip>
        <telephone>+98 41 3476 7121</telephone>
        <email>reyhane.abri@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reyhaneh Abri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Operating room-alzahra hospital- south artesh st</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138663134</zip>
        <telephone>+98 41 3476 7121</telephone>
        <email>reyhane.abri@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Female with physical condition ASA(American Society of Anesthesiologists)  class I or II
In the age range of 60-18 years
candidate for laparoscopic gynecological surgery
Patient consent to study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Existence of any contraindications to regional anesthesia
Sensitivity to local anesthetics
Excessive obesity
Accompanying systemic diseases such as any history of cardiovascular, pulmonary, hepatic, renal, etc.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T88.59</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anesthesia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group:37 patients will be placed under general anesthesia with induction and maintenance of anesthesia with 1% intravenous propofol drug of Dongkook pharmaco company made in Korea and endotracheal intubation will be performed for controlled breathing during surgery and hemodynamic and respiratory consequences (such as Systolic and diastolic blood pressure, mean arterial pressure, heart rate, saturation of peripheral oxygen, severity of nausea and vomiting, severity of pain )during and after surgery will be assessed.</i_keyword>
      <i_keyword>Intervention group:37 patients undergoing spinal anesthesia with spinal injection of topical anesthetic bupivacaine 5% hyperbaric manufactured by aspen company and spontaneous respiration will be maintained and hemodynamic and respiratory consequences (such as systolic and diastolic blood pressure, mean arterial pressure, heart rate, saturation of peripheral oxygen, severity of nausea and vomiting, severity of pain)during and after surgery will be assessed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic and diastolic blood pressure. Timepoint: From the beginning of anesthesia to 30th minute,every 5 minutes and after that every 15minutes and in recovery section until discharging,every 10 minutes. Method of measurement: Mercury barometer.</prim_outcome>
      <prim_outcome>Mean arterial pressure(MAP). Timepoint: From the beginning of anesthesia to 30th minute,every 5 minutes and after that every 15minutes and in recovery section until discharging,every 10 minutes. Method of measurement: Mercury barometer.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: From the beginning of anesthesia to 30th minute,every 5 minutes and after that every 15minutes and in recovery section until discharging,every 10 minutes. Method of measurement: Counting in each minutes.</prim_outcome>
      <prim_outcome>Saturation of peripheral oxygen. Timepoint: From the beginning of anesthesia to 30th minute,every 5 minutes and after that every 15minutes and in recovery section until discharging,every 10 minutes. Method of measurement: Via the Pulse Oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Severity of postoperative nausea and vomiting. Timepoint: Every 5 minutes in recovery until discharge from recovery and transfer to ward. Method of measurement: scoring by (0=non, 1=nausea, 2=vomiting, 3=vomiting &gt;2 times).</sec_outcome>
      <sec_outcome>Severity of postoperative pain. Timepoint: Recovery and at 3, 6, 12,18 and 24 hours postoperatively. Method of measurement: Four Numerical Verbal Rating Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-25</approval_date>
        <contact_name>Ethic Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor for research, Golgasht Street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
